European Journal of Cancer Prevention

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

Retrieved on: 
Mercoledì, Settembre 20, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

Key Points: 
  • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
  • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
  • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
  • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

Retrieved on: 
Venerdì, Marzo 17, 2023
Risk, High Risk, University, CP-GEP, European Journal of Cancer Prevention, Cancer, Research, Gene expression, Gene expression profiling, RFS, Medicare, Patient, Melanoma, SAN, Active surveillance of low-risk papillary thyroid microcarcinoma, Diagnosis, Lymph node, European Journal, Inflammation, Pharmaceutical industry, Medical imaging

The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.

Key Points: 
  • The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.
  • It found that when combined with clinicopathologic factors, the CP-GEP model can be used to stratify these patients into high risk and low risk cohorts for disease recurrence.
  • Specifically, the patients determined to have Low Risk have an almost five times favorable 5-year recurrence free survival (RFS) over the CP-GEP High Risk patients in stage I/II melanoma, with 93% of low-risk patients are recurrence-free 5 years after diagnosis [2].
  • "The Merlin test can drive a profound economic benefit by significantly reducing the number of SLNB procedures performed on Low Risk melanoma patients.

Independent study shows favorable long term prognosis for CP-GEP Low Risk melanoma patients

Retrieved on: 
Venerdì, Marzo 17, 2023
Risk, High Risk, University, CP-GEP, European Journal of Cancer Prevention, Cancer, Research, Gene expression, Gene expression profiling, RFS, Medicare, Patient, Melanoma, SAN, Active surveillance of low-risk papillary thyroid microcarcinoma, Diagnosis, Lymph node, European Journal, Inflammation, Pharmaceutical industry, Medical imaging

The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.

Key Points: 
  • The University of Tuebingen (Germany) study analyzed 543 patients diagnosed with stage I/II primary cutaneous melanoma between 2000 and 2017.
  • It found that when combined with clinicopathologic factors, the CP-GEP model can be used to stratify these patients into high risk and low risk cohorts for disease recurrence.
  • Specifically, the patients determined to have Low Risk have an almost five times favorable 5-year recurrence free survival (RFS) over the CP-GEP High Risk patients in stage I/II melanoma, with 93% of low-risk patients are recurrence-free 5 years after diagnosis [2].
  • "The Merlin test can drive a profound economic benefit by significantly reducing the number of SLNB procedures performed on Low Risk melanoma patients.

Genetype for Ovarian Cancer Published in Prestigious European Journal of Cancer Prevention

Retrieved on: 
Mercoledì, Novembre 9, 2022
GLOBE, Health, Monash University, Guideline, GTG, Risk, American Cancer Society, Incidence, Death, Diagnosis, Mortality, European Journal, NASDAQ, Genetypes, Science, ASX, Journal, Ovarian cancer, Breast cancer, Woman, UK Biobank, European Journal of Cancer Prevention, Medical device, Birth control

This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Cancer Prevention.

Key Points: 
  • This 10 year prospective cohort study utilizes data from more than 190,000 women and has been published in the prestigious European Journal of Cancer Prevention.
  • Ovarian cancer is one of the top five cancer-associated causes of death in women (American Cancer Society, 2022).
  • GeneType Risk Assessment Test for Ovarian Cancer is able to identify general population women across a spectrum of risk allowing for more nuanced approaches to ovarian cancer screening and risk-reduction.
  • ASX announcement titled: "Journal of Precision Medicine publication confirms GeneType Risk Test outperforms traditional risk assessments for breast cancer".